Hamilton Thorne Ltd.TSX: HTL

Hamilton Thorne announces 2010 second quarter results

· Issued by Hamilton Thorne Ltd. via CNW

Aug. 23, 2010 (Canada NewsWire Group) --

- Sales up 57% year-over-year and 36% on a sequential basis -

TSX VENTURE: HTL

TORONTO, Aug. 23 /CNW/ - Hamilton Thorne Ltd. (TSX-V: HTL), a leading provider of advanced laser systems and instruments for the stem cell research and fertility clinic markets, today reported operational and financial results for the second quarter ended June 30, 2010.

"The improving fundamentals of the stem cell and regenerative medicine market are reflected in our strong sales growth. Sales increased as a direct result of the increased demand for our laser products with our quarterly sales up 57% year-over-year and sales up 36% over the first quarter," said Meg Spencer, Chief Executive Officer of Hamilton Thorne Ltd. "Our focus to expand our sales reach into our markets is highlighted by the vendor partnership that we secured with Leica Microsystems, a leading micro-optics manufacturer. This partnership allows us dramatically to advance our penetration into the regenerative medicine market, to develop sales strategy collaboratively and ultimately to provide us with sales growth in North America. We intend to pursue additional distribution partnerships with leaders in the market to continue to grow our presence in labs worldwide."

Highlights

    <<
    -   Partnered with Leica Microsystems GmbH of Wetzlar, Germany, a leading
        global designer and producer of innovative high-tech precision optics
        systems for the analysis of microstructures. The vendor partnership
        enables Hamilton Thorne to draw on Leica Microsystems' specialized
        technical sales group and provides for the companies to work
        collaboratively to develop sales strategy and exchange leads to
        increase market penetration.
    -   Launched Staccato(TM) multi-pulse laser system at the 8th Annual
        Meeting of the International Society of Stem Cell Research (ISSCR),
        June 16-19, 2010, in San Francisco, CA. Staccato(TM) will add to the
        functionality of the XYClone(R) laser system, providing the ability
        of near-continuous application of the laser to the sample through
        rapid pulsing of the beam.
    -   Previewed the breakthrough Stiletto(TM) laser system, which is
        currently in beta site testing. The Stiletto(TM) laser system
        combines a proprietary laser, controller software and an automated
        stage for high speed scoring and separation of stem cell colonies.
        The Company intends to complete beta site testing and launch
        Stiletto(TM) in the second half of 2010.
    -   Subsequent to quarter end, closed debentures offering of
        US$1.25 million.
    >>

Financial Results

All amounts are in US dollars, unless specified otherwise, and results expressed in accordance with Canadian Generally Accepted Accounting Principles (GAAP).

For the three months ended June 30, 2010, the Company recorded sales of $1,608,520, compared to $1,018,870 for the same period last year. The sales increases were attributable primarily to increased demand for its laser products and revenues from its Hawk-I installation. The Company's customers in the regenerative medicine field primarily use the Company's products in research applications. During 2009, the Company's sales, particularly in North America and Europe, were adversely impacted by budget freezes and extended purchasing cycles for research products. These issues have improved in 2010.

Cost of sales for the three months ended June 30, 2010 was $599,199, compared to $404,212 for the same period last year. Gross margins as a percent of sales improved for the comparable quarters to 62.7% from 60.3%. The improvements in the three month period were due primarily to the fact that manufacturing costs are largely fixed and did not increase proportionately with the increase in sales which more than offset the higher material cost due to aggressive pricing offered to establish a reference site for the Hawk-i product line.

For the three months ended June 30, 2010, total operating expenses were $1,310,926, compared to $1,047,581 for the same period last year.

Research and development (R&D) expenses for the three months ended June 30, 2010 were $228,947, compared with $220,924 for the same period last year. Sales and marketing expenses for the three months ended June 30, 2010 were $595,107, compared with $467,469 for the same period last year. General and administrative expenses for the three months ended June 30, 2010 were $486,872, compared with $359,188 for the same period last year.

The net loss for the quarter ended June 30, 2010 was $363,770, a decrease from the net loss of $521,584 for the same period of the previous year. The improvement was due to the increased sales and related margins along with decreased interest offset by increased operating expenses.

The Company also announced that it will grant 162,818 stock options to an officer of the Company pursuant to its stock option plan effective August 25, 2010 at the closing price on the date of grant. The options vest quarterly, with 1/16 vested at time of grant and 1/16 vesting each subsequent quarter, with an expiry ten years from the date of grant.

As at June 30, 2010, the Company's available cash and cash equivalents (including cash availability under its credit line) amounted to $276,703.

As of June 30, 2010 the Company had 24,415,157 common shares, 5,500,005 warrants, 3,542,756 options, and 440,001 agent compensation options outstanding.

The financial statements are available on www.sedar.com.

About Hamilton Thorne Ltd. (www.hamiltonthorne.com)

Hamilton Thorne's advanced laser systems and instruments are rapidly emerging as the dominant products to facilitate precise procedures in the stem cell research and fertility clinic markets. Hamilton Thorne's lead products, the ZILOS-tk and XYClone laser systems, attach to standard inverted microscopes and operate as robotic micro-surgeons, significantly reducing time and increasing efficiency in key in-vitro fertilization, stem cell, embryo, reproductive toxicology, and living cell procedures.

Hamilton Thorne's growing customer base includes pharmaceutical companies, biotechnology companies, fertility clinics, university research centers, and other commercial and academic research establishments worldwide. Current customers include world-leading research labs such as Harvard University, MIT, Yale, DuPont, Monsanto, Charles River Labs, Jackson Labs, Merck, Novartis, Pfizer, Oxford University, and Cambridge.

Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.

Certain information in this press release may contain forward-looking statements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in filings by the Company with the Canadian securities regulators, which filings are available at www.sedar.com.

Financials results included below:

    <<
                                                         Hamilton Thorne Ltd.
                                                 Consolidated Balance Sheets
                                   As at June 30, 2010 and December 31, 2009
                                      (Expressed in U.S. Dollars - unaudited)
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
                                                           2010         2009
    -------------------------------------------------------------------------

    Assets
    Current
      Cash and cash equivalents                           6,703    1,356,371
      Accounts receivable                             1,084,947      499,875
      Inventories                                       569,882      512,300
      Prepaid expenses and other current assets          53,027       72,689
      Note receivable, officer                                -       23,813
    -------------------------------------------------------------------------
                                                      1,714,559    2,465,048
      Capital assets                                    111,285       90,481
      Other assets                                      125,656       72,454
    -------------------------------------------------------------------------
                                                      1,951,500    2,627,983
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

    Liabilities
    Current
      Accounts payable and accrued liabilities        1,496,017    1,171,562
      Notes payable                                      54,159       83,037
      Capital lease obligations, current                  5,753        5,753
      Deferred revenue                                  166,769       35,881
    -------------------------------------------------------------------------
                                                      1,722,698    1,296,233
      Capital lease obligations, non-current              4,537        7,904
      Long-term debt                                  4,780,000    5,050,000
    -------------------------------------------------------------------------
                                                      6,507,235    6,354,137
    -------------------------------------------------------------------------

    Shareholders' Equity (Deficiency)
      Common shares                                  24,345,752   24,341,938
      Warrants                                          344,949      344,949
      Contributed surplus                               279,267      199,767
      Accumulated deficit                           (29,525,703) (28,612,808)
    -------------------------------------------------------------------------
                                                     (4,555,735)  (3,726,154)
    -------------------------------------------------------------------------
                                                      1,951,500    2,627,983
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------



                                                         Hamilton Thorne Ltd.
    Consolidated Statements of Operations and Comprehensive Loss and Deficit
                                For the periods ended June 30, 2010 and 2009
                                      (Expressed in U.S. Dollars - unaudited)

                                        Six Months              Three Months
                                 2010         2009         2010         2009
    -------------------------------------------------------------------------

    Sales                   2,789,207    2,134,424    1,608,520    1,018,870
    Cost of sales           1,069,685      823,073      599,199      404,212
    -------------------------------------------------------------------------
                            1,719,522    1,311,351    1,009,321      614,658
    -------------------------------------------------------------------------
    Expenses
      Research and
       development            479,254      397,697      228,947      220,924
      Sales and marketing   1,080,794      910,004      595,107      467,469
      General and
       administrative         940,255      741,653      486,872      359,188
    -------------------------------------------------------------------------
                            2,500,303    2,049,354    1,310,926    1,047,581
    -------------------------------------------------------------------------

    Loss from operations     (780,781)    (738,003)    (301,605)    (432,923)

    Other income (expense)
      Interest expense,
       net, including
       accretion             (132,114)    (173,057)     (62,165)    (88,661)
    -------------------------------------------------------------------------

    Net loss and
     comprehensive loss      (912,895)    (911,060)    (363,770)    (521,584)
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

    Accumulated deficit
     at beginning of
     period:              (28,612,808) (27,225,220) (29,161,933) (27,614,696)

    Accumulated deficit
     at end of period:    (29,525,703) (28,136,280) (29,525,703) (28,136,280)

    Loss per share
      Basic                    $(0.04)      $(0.06)      $(0.01)      $(0.03)
      Diluted                  $(0.04)      $(0.06)      $(0.01)      $(0.03)

    Weighted average
     number of common
     shares outstanding
      Basic                24,415,157   16,035,067   24,415,157   16,035,067
      Diluted              24,917,072   16,035,067   24,939,580   16,035,067




                                                         Hamilton Thorne Ltd.
                                       Consolidated Statements of Cash Flows
                                For the periods ended June 30, 2010 and 2009
                                      (Expressed in U.S. Dollars - unaudited)

                                        Six Months              Three Months
                                 2010         2009         2010         2009
    -------------------------------------------------------------------------

    Cash flows from
     operating activities
    Net loss for the year    (912,895)    (911,060)    (363,770)    (521,584)
    Adjustments to
     reconcile net loss
     to net cash used in
     operating activities:
      Depreciation and
       amortization            31,191       57,402       16,164       27,951
      Non-cash interest
       expense/accretion            -       75,378            -       37,897
      Share-based
       compensation
       expense                 79,500       19,450       39,750        9,700
      Changes in non-cash
       operating assets
       and liabilities:
        Accounts
         receivable          (585,072)     475,576     (502,981)      30,246
        Inventories           (57,582)       5,773      (57,891)        (486)
        Prepaids and other
         current assets        43,475       (8,162)      12,921      (23,914)
        Other assets          (57,000)      (9,402)           -       (7,734)
        Accounts payable
         and accrued
         liabilities          324,455       24,361      342,087      162,459
        Deferred revenue      130,888       (3,355)     127,971        5,770
    -------------------------------------------------------------------------
                           (1,003,040)    (274,039)    (385,749)    (279,695)
    -------------------------------------------------------------------------

    Cash flows from
     investing activities
      Purchase of capital
       assets                 (48,197)     (58,017)     (11,101)     (16,493)
    -------------------------------------------------------------------------

    Cash flows from
     financing activities
      Proceeds from debt      754,454      447,714      256,411      277,714
      Private placement
       costs refunded           3,814            -        3,814            -
      Payments on debt     (1,056,699)    (117,767)    (553,015)      (5,345)
    -------------------------------------------------------------------------
                             (298,431)     329,947     (292,790)     272,369
    -------------------------------------------------------------------------

    Net Increase (decrease)
     in cash and cash
     equivalents           (1,349,668)      (2,109)    (689,640)     (23,819)
    Cash and cash
     equivalents,
     beginning of
     period                 1,356,371        5,029      696,343       26,739
    -------------------------------------------------------------------------
    Cash and cash
     equivalents, end
     of period                  6,703        2,920        6,703        2,920
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
    >>

David Wolf, President, Hamilton Thorne Ltd., 978-299-1715, ir@hamiltonthorne.com; Ross Marshall, The Equicom Group, 416.815.0700 x238, rmarshall@equicomgroup.com

Hamilton Thorne Ltd. on 6ix

Story so far

Earlier from Hamilton Thorne

Later from Hamilton Thorne

All Hamilton Thorne news releases